Stelis Biopharma an emerging biopharmaceutical Contract Development and Manufacturing Organization CDMO and the biologics arm of Strides Pharma Science today announced that it received the Establishment Inspection Report EIR from US Food and Drug Administration USFDA or agency for the Drug Products DP facility inspection that was completed at its flagship manufacturing site Unit 2 at Bengaluru India This outcome for the DP facility comes after the USFDA on-site Pre-Approval Inspection PAI at Stelis flagship manufacturing facility for several product submissions by the partners to the agency The Unit 2 facility has high-end automated DP lines integrated with isolators to convert drug substances DS into stable formulations and fill finish within the same facility in all injectable formats including cartridges pen devices auto-injectors pre-filled syringes liquid and lyophilized vials
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
